Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo

Back to Search
Print
Bookmark Trial

NCT00351611

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Neurological Associates
Richmond, Virginia, 23229, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Partial Epilepsies
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Epilepsy partial seizure subjects.

- Currently taking 1 to 3 antiepileptic drugs.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Pre-existing eye diseases (glaucoma).


- Insufficient response to pregabalin in the treatment of partial seizure, or patients
currently receiving pregabalin treatment.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Partial EpilepsiesDrug Use Investigation Of Gabapentin
NCT00567268
ALL GENDERS
0+
years
MULTIPLE SITES
Partial EpilepsiesA Phase III Open-Label Extension Study Of Gabapentin As Adjunctive Therapy In Japanese Pediatric Patients With Partial Seizures
NCT00620555
  1. Obu-shi,Morioka-machi, Aichi
  2. Jonan-ku, Fukuoka
  3. Kobe, Hyogo
  4. Suma-Ku,Kobe, Hyogo
  5. Kanazawa, Ishikawa
  6. Zentsuuji, Kagawa
  7. Yokohama, Kanagawa Pref.
  8. Sendai-shi, Miyagi-ken
  9. Showa-Ku, Nagoya
  10. Niigata-shi, Niigata
  11. Kurashiki-City, Okayama Pref.
  12. Okayama-shi, Okayama
  13. Izumi-shi, Osaka
  14. Miyakojima-ku, Osaka
  15. Suita, Osaka
  16. Shizuoka-shi, Shizuoka
  17. Kodaira, Tokyo
  18. Setagaya-ku, Tokyo
  19. Shinjuku-ku, Tokyo
  20. Hiroshima,
  21. Saitama,
  22. Yamagata,
ALL GENDERS
3 Years+
years
MULTIPLE SITES
Partial EpilepsiesSafety, Tolerability, and Pharmacokinetic Study of Pregabalin in Pediatric Patients With Partial Onset Seizures
NCT00437281
  1. Mobile, Alabama
  2. Mobile, Alabama
  3. Phoenix, Arizona
  4. Jonesboro, Arkansas
  5. Little Rock, Arkansas
  6. San Francisco, California
  7. Gulf Breeze, Florida
  8. Pensacola, Florida
  9. Tampa, Florida
  10. Tampa, Florida
  11. Springfield, Missouri
  12. Buffalo, New York
  13. Durham, North Carolina
  14. Houston, Texas
  15. San Antonio, Texas
  16. Seoul,
  17. Mexico, DF
  18. Guadalajara, Jalisco
ALL GENDERS
1 Month+
years
MULTIPLE SITES
Partial EpilepsiesSafety and Efficacy of Gabapen for Pediatric (Regulatory Post Marketing Commitment Plan)
NCT01441401
ALL GENDERS
3 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
Official Title  ICMJE PROSPECTIVE RANDOMIZED 12-WEEK CONTROLLED STUDY OF VISUAL FIELD CHANGE IN SUBJECTS WITH PARTIAL SEIZURES RECEIVING PREGABALIN OR PLACEBO
Brief Summary Patients with partial seizures currently taking 1-3 antiepileptic medications will have a 50:50 chance to receive Lyrica 300 mg per day or placebo (no active ingredients) added on to their current medications for 3 months. Neither the study doctor nor the patient will know the medication assignment. Vision testing will be performed prior to receiving the study treatment and at the end of the study to see if there are any changes.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Epilepsies, Partial
Intervention  ICMJE
  • Drug: Lyrica (pregabalin)
    150 mg twice a day, oral administration
  • Drug: placebo
    Twice a day, oral administration
Study Arms  ICMJE
  • Experimental: Active
    Active drug
    Intervention: Drug: Lyrica (pregabalin)
  • Placebo Comparator: Placebo
    placebo comparator
    Intervention: Drug: placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: October 19, 2020)		187
Original Enrollment  ICMJE
 (submitted: July 11, 2006)		284
Actual Study Completion Date  ICMJE February 4, 2020
Actual Primary Completion Date February 4, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Epilepsy partial seizure subjects.
  • Currently taking 1 to 3 antiepileptic drugs.

Exclusion Criteria:

  • Pre-existing eye diseases (glaucoma).
  • Insufficient response to pregabalin in the treatment of partial seizure, or patients currently receiving pregabalin treatment.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Bulgaria,   Czechia,   Hungary,   India,   Korea, Republic of,   Mexico,   Poland,   Thailand,   United States
Removed Location Countries Czech Republic
 
Administrative Information
NCT Number  ICMJE NCT00351611
Other Study ID Numbers  ICMJE A0081096
2009-014269-25 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer ( Pfizer's Upjohn has merged with Mylan to form Viatris Inc. )
Study Sponsor  ICMJE Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP